Enasidenib (mesylate)

Synopsis, Chemistry

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 1650550-25-6, Ag-221 mesylate, Enasidenib mesilate, Enasidenib methanesulfonate, Enasidenib (mesylate), Uf6pc17xav

Molecular Formula

C₂₀H₂₁F₆N₇O₄S

Molecular Weight

569.5 g/mol

InChI Key

ORZHZQZYWXEDDL-UHFFFAOYSA-N

FDA UNII

UF6PC17XAV

Enasidenib Mesylate is the mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.

1 2D Structure

Enasidenib (mesylate)

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

methanesulfonic acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol

2.1.2 InChI

InChI=1S/C19H17F6N7O.CH4O3S/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25;1-5(2,3)4/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32);1H3,(H,2,3,4)

2.1.3 InChI Key

ORZHZQZYWXEDDL-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O.CS(=O)(=O)O

2.2 Other Identifiers

2.2.1 UNII

UF6PC17XAV

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. 1650550-25-6

2. Ag-221 Mesylate

3. Enasidenib Mesilate

4. Enasidenib Methanesulfonate

5. Enasidenib (mesylate)

6. Uf6pc17xav

7. Enasidenib Mesylate [usan]

8. Cc-90007

9. 1650550-25-6 (mesylate)

10. Enasidenib Mesylate (usan)

11. 2-propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1)

12. 2-methyl-1-[4-(6-trifluoromethyl-pyridin-2-yl)-6-(2-trifluoromethyl-pyridin-4-ylamino)-[1,3,5]triazin-2-ylamino]-propan-2-ol Mesylate

13. Methanesulfonic Acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol

14. Unii-uf6pc17xav

15. Idhifa (tn)

16. Chembl3989931

17. Enasidenib Mesylate [mi]

18. Schembl16448052

19. Dtxsid501027943

20. Bcp26166

21. Ex-a1972

22. Enasidenib Mesylate [who-dd]

23. Hy-18690a

24. S4929

25. Enasidenib Mesylate; Ag-221 Mesylate

26. At36098

27. Cs-7541

28. Enasidenib Mesylate [orange Book]

29. Ac-31319

30. D11044

31. Q27291054

32. 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)- 6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin- 2-yl)amino)propan-2-ol Methanesulfonate

2.4 Create Date

2015-02-23

3 Chemical and Physical Properties

Molecular Formula	C₂₀H₂₁F₆N₇O₄S
Molecular Weight	569.5 g/mol
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	17
Rotatable Bond Count	6
Exact Mass	569.12799232 g/mol
Monoisotopic Mass	569.12799232 g/mol
Topological Polar Surface Area	172 Å²
Heavy Atom Count	38
Formal Charge	0
Complexity	727
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2